Welcome to the IGCS 2021
Virtual Meeting
| Opening Ceremony and Plenary 1: Oral Abstract Presentations | 13:00 - 14:00 | JOIN |
| Debate Your Colleague | 14:05 - 15:05 | JOIN |
| Tumor Board | 15:10 - 16:40 | JOIN |
| Regional Session: Updates in Gynecologic Oncology in Italy | 15:10 - 16:40 | JOIN |
| Master Session: Cervical Cancer | 16:45 - 18:45 | JOIN |
| New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy - Industry Symposium Supported by Clinical Care Options LLC | 18:50 - 19:50 | JOIN |
| Plenary 2: Oral Abstract Presentations | 12:00 - 13:00 | JOIN |
| Rare tumors including GTN | 13:05 - 14:05 | JOIN |
| Surgical Debate: HIPEC for ovarian cancer | 13:05 - 14:05 | JOIN |
| Presidential Plenary 3 | 14:10 - 15:10 | JOIN |
| Master Session: Uterine Cancer | 15:15 - 17:15 | JOIN |
| Debate Your Colleague 2 - Should all newly diagnosed ovarian cancer patients receive a PARPi as maintenance treatment? | 17:20 - 18:20 | JOIN |
| The evolving treatment landscape of gynecological tumors - Industry Symposium Supported by GSK | 18:25 - 19:25 | JOIN |
| Mirvetuximab Soravtansine an Antibody-Drug Conjugate Targeting the Folate Receptor for Women with Ovarian Cancer - Industry Symposium Supported by ImmunoGen | 18:25 - 19:25 | JOIN |
| 2021 IGCS Business Meeting | 19:30 - 20:00 | JOIN |
| Awards Ceremony & Plenary 4: Seminal Abstract Presentations | 12:45 - 14:15 | JOIN |
| Updates in radiation oncology and brachytherapy | 14:20 - 15:50 | JOIN |
| Master Session: Vulvar Cancer | 15:55 - 17:55 | JOIN |
| Oral Featured Posters - LIVE | 17:00 - 18:00 | JOIN |
| Surgical Debate: MIS for cervical cancer | 17:00 - 18:00 | JOIN |
| Plenary 5: Oral Abstract Presentations | 18:00 - 19:00 | JOIN |
| Platinum-Resistant Ovarian Cancer: Treatment Landscape and Future Opportunities - A Panel Discussion - Industry Symposium Supported by Novocure | 19:05 - 20:05 | JOIN |
| Solutions to Address Missed Opportunities for Genetic Testing Globally - Industry Symposium Supported by Myriad Genetics GmbH | 19:05 - 20:05 | JOIN |
| Master Session: Ovarian Cancer | 12:00 - 14:30 | JOIN |
| Plenary 6 | 14:35 - 15:35 | JOIN |
| Controversies in the use of SLN for endometrial cancer | 15:40 - 16:40 | JOIN |
| How Cemiplimab is EMPOWERING change in the management of recurrent cervix cancer - Industry Symposium Supported by IGCS | 16:45 - 17:45 | JOIN |
| The Evolution of NGS for Gynecologic Malignancies: Delivering the Future for More Precise Treatment - Industry Symposium Supported by Caris Life Sciences | 16:45 - 17:45 | JOIN |